Baker McKenzie CVBA/SCRL
We only have limited information for this firm. Consider the following firms which have provided more information:
Baker McKenzie CVBA/SCRL's banking and corporate finance practice is particularly well-regarded for its connections with corporate clients in the life sciences sector, who instruct the team to advise on high-value, cross-border acquisition financings, capital raising transactions, public offerings, and recapitalistation mandates. The team is also active for lender clients, working for standout banks such as ING and BNP Paribas Fortis on refinancing matters and a growing volume of sustainability-linked finance transactions. Institutional lending expert Michael Van Acker co-heads the practice with capital markets and corporate finance specialist Roel Meers following the departure of former practice head Antoine De Raeve in May 2023. Further key contacts in the team include Joren Janseunne, who was promoted to partner in July 2023 and chiefly advises on securitisations and financing matters.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Very competent both from a local legal perspective and from an international point of view, being present in several continents.’
‘The team has unique experience in ECM, debt and restructuring markets, and has the manpower to bring complex deals home.’
Abbreviated data is displayed for this firm.
Key clients
- Mithra Pharmaceuticals
- Sequana Medical NV
Abbreviated data is displayed for this firm.
Work highlights
- Advised Biocartis Group on a €201m recapitalisation.
- Advised KBC Bank and other lenders in connection with the ECA-backed financing of the expansion of the port of Montevideo by Terminal Cuenca Del Plata S.A.
Abbreviated data is displayed for this firm.